دورية أكاديمية
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
| العنوان: | Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART |
|---|---|
| المؤلفون: | Lambert-Niclot S., George E. C., Pozniak A., White E., Schwimmer C., Jessen H., Johnson M., Dunn D., Perno C. F., Clotet B., Plettenberg A., Blaxhult A., Palmisano L., Wittkop L., Calvez V., Marcelin A. G., Raffi F., Dedes N., Chene G., Allavena C., Autran B., Antinori A., Bucciardini R., Vella S., Horban A., Arribas J., Babiker A. G., Boffito M., Pillay D., Franquet X., Schwarze S., Grarup J., Fischer A., Richert L., Wallet C., Diallo A., Molina J. -M., Saillard J., Moecklinghoff C., Stellbrink H. -J., Van Leeuwen R., Gatell J., Sandstrom E., Flepp M., Ewings F., Hudson F., Pearce G., Quercia R., Rogatto F., Leavitt R., Nguyen B. -Y., Goebel F., Marcotullio S., Kaur N., Sasieni P., Spencer-Drake C., Peto T., Miller V., Arnault F., Boucherie C., Jean D., Paniego V., Paraina F., Rouch E., Soussi M., Taieb A., Termote M., Touzeau G., Cursley A., Dodds W., Hoppe A., Kummeling I., Pacciarini F., Paton N., Russell C., Taylor K., Ward D., Aagaard B., Eid M., Gey D., Jensen B. G., Jakobsen M. -L., Jansson P. O., Jensen K., Joensen Z. M., Larsen E. M., Pahl C., Pearson M., Nielsen B. R., Reilev S. S., Christ I., Lathouwers D., Manting C., Mendy B. Y., Metro A., Couffin-Cadiergues S., Knellwolf A. -L., Palmisiano L., Aznar E., Barea C., Cotarelo M., Esteban H., Girbau I., Moyano B., Ramirez M., Saiz C., Sanchez I., Yllescas M., Binelli A., Colasanti V., Massella M., Anagnostou O., Gioukari V., Touloumi G., Schmied B., Rieger A., Vetter N., De Wit S., Florence E., Vandekerckhove L., Gerstoft J., Mathiesen L., Katlama C., Cabie A., Cheret A., Dupon M., Ghosn J., Girard P. -M., Goujard C., Levy Y., Morlat P., Neau D., Obadia M., Perre P., Reynes J., Tattevin P., Ragnaud J. M., Weiss L., Yazdan Y., Yeni P., Zucman D., Behrens G., Esser S., Fatkenheuer G., Hoffmann C., Rockstroh J., Schmidt R., Stephan C., Unger S., Hatzakis A., Daikos G. L., Papadopoulos A., Skoutelis A., Banhegyi D., Mallon P., Mulcahy F., Andreoni M., Bonora S., Castelli F., Monforte A. D., Di Perri G., Galli M., Lazzarin A., Mazzotta F., Carlo T., Vullo V., Prins J., Richter C., Verhagen D., Van Eeden A., Doroana M., Antunes F., Maltez F., Sarmento-Castro R., Garcia J. G., Aldeguer J. L., Domingo P., Gatell J. M., Knobel H., Marquez M., Miralles M. P., Portilla J., Soriano V., Tellez M. -J., Thalme A., Gisslen M., Winston A., Fox J., Gompels M., Herieka E., Leen C., Teague A., Williams I., Boyd M. A., Moller N. F., Larsen E. F. M., Piroth L., Le Moing V., Wit F. W. N. M., Kowalska J., Berenguer J., Moreno S., Muller N. J., Torok E., Post F., Angus B., Boucher C., Collins S., Lambert S., Marcelin A. -G., Ammassari A., Stoehr W., Schmidt R. E., Odermarsky M., Smith C., Thiebaut R., De La Serna J. I. B., Castagna A., Furrer H. -J., Mocroft A., Reiss P., Fragola V., Lauriola M., Murri R., Nieuwkerk P., Spire B., Volny-Anne A., West B., Amieva H., Codina J. M. L., Braggion M., Foca E. |
| المساهمون: | Lambert-Niclot, S., George, E. C., Pozniak, A., White, E., Schwimmer, C., Jessen, H., Johnson, M., Dunn, D., Perno, C. F., Clotet, B., Plettenberg, A., Blaxhult, A., Palmisano, L., Wittkop, L., Calvez, V., Marcelin, A. G., Raffi, F., Dedes, N., Chene, G., Allavena, C., Autran, B., Antinori, A., Bucciardini, R., Vella, S., Horban, A., Arribas, J., Babiker, A. G., Boffito, M., Pillay, D., Franquet, X., Schwarze, S., Grarup, J., Fischer, A., Richert, L., Wallet, C., Diallo, A., Molina, J. -M., Saillard, J., Moecklinghoff, C., Stellbrink, H. -J., Van Leeuwen, R., Gatell, J., Sandstrom, E., Flepp, M., Ewings, F., Hudson, F., Pearce, G., Quercia, R., Rogatto, F., Leavitt, R., Nguyen, B. -Y., Goebel, F., Marcotullio, S., Kaur, N., Sasieni, P., Spencer-Drake, C., Peto, T., Miller, V., Arnault, F., Boucherie, C., Jean, D., Paniego, V., Paraina, F., Rouch, E., Soussi, M., Taieb, A., Termote, M., Touzeau, G., Cursley, A., Dodds, W., Hoppe, A., Kummeling, I., Pacciarini, F., Paton, N., Russell, C., Taylor, K., Ward, D., Aagaard, B., Eid, M., Gey, D., Jensen, B. G., Jakobsen, M. -L., Jansson, P. O., Jensen, K., Joensen, Z. M., Larsen, E. M., Pahl, C., Pearson, M., Nielsen, B. R., Reilev, S. S., Christ, I., Lathouwers, D., Manting, C., Mendy, B. Y., Metro, A., Couffin-Cadiergues, S. |
| سنة النشر: | 2016 |
| المجموعة: | Università degli Studi di Brescia: OPENBS - Open Archive UniBS |
| مصطلحات موضوعية: | Adult, Anti-HIV Agent, CD4 Lymphocyte Count, Female, Follow-Up Studie, HIV Infection, HIV-1, Human, Male, Microbial Sensitivity Test, Middle Aged, Mutation, Treatment Failure, Treatment Outcome, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Viral Load |
| الوصف: | OBJECTIVES: To describe the pattern of drug resistance at virological failure in the NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either tenofovir/emtricitabine or raltegravir). METHODS: Genotypic testing was performed at baseline for reverse transcriptase (RT) and protease genes and for RT, protease and integrase (IN) genes for patients with a confirmed viral load (VL) >50 copies/mL or any single VL >500 copies/mL during or after week 32. RESULTS: A resistance test was obtained for 110/805 (13.7%) randomized participants qualifying for resistance analysis (61/401 of participants in the raltegravir arm and 49/404 of participants in the tenofovir/emtricitabine arm). No resistance-associated mutation (RAM) was observed in the tenofovir/emtricitabine plus darunavir/ritonavir arm, and all further analyses were limited to the raltegravir plus darunavir arm. In this group, 15/55 (27.3%) participants had viruses with IN RAMs (12 N155H alone, 1 N155H + Q148R, 1 F121Y and 1 Y143C), 2/53 (3.8%) with nucleotide analogue RT inhibitor RAMs (K65R, M41L) and 1/57 (1.8%) with primary protease RAM (L76V). The frequency of IN mutations at failure was significantly associated with baseline VL: 7.1% for a VL of <100,000 copies/mL, 25.0% for a VL of ≥100,000 copies/mL and <500,000 copies/mL and 53.8% for a VL of ≥500,000 copies/mL (PTREND = 0.007). Of note, 4/15 participants with IN RAM had a VL < 200 copies/mL at time of testing. CONCLUSIONS: In the NEAT001/ANRS143 trial, there was no RAM at virological failure in the standard tenofovir/emtricitabine plus darunavir/ritonavir regimen, contrasting with a rate of 29.5% (mostly IN mutations) in the raltegravir plus darunavir/ritonavir NRTI-sparing regimen. The cumulative risk of IN RAM after 96 weeks of follow-up in participants initiating ART with raltegravir plus darunavir/ritonavir was 3.9%. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26702926; info:eu-repo/semantics/altIdentifier/wos/WOS:000374232500031; volume:71; issue:4; firstpage:1056; lastpage:1062; numberofpages:7; journal:JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY; http://hdl.handle.net/11379/518646Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84964317330; http://jac.oxfordjournals.orgTest/ |
| DOI: | 10.1093/jac/dkv427 |
| الإتاحة: | https://doi.org/10.1093/jac/dkv427Test http://hdl.handle.net/11379/518646Test http://jac.oxfordjournals.orgTest/ |
| رقم الانضمام: | edsbas.415B8C4E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jac/dkv427 |
|---|